SRR6013487
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.140
- TNFA_SIGNALING_VIA_NFKB+0.100
- UV_RESPONSE_DN+0.080
- P53_PATHWAY+0.060
- ESTROGEN_RESPONSE_EARLY+0.030
- ALLOGRAFT_REJECTION+0.020
- KRAS_SIGNALING_DN+0.020
- IL2_STAT5_SIGNALING+0.010
- HEDGEHOG_SIGNALING+0.000
- WNT_BETA_CATENIN_SIGNALING-0.010
Top 10 suppressed
- E2F_TARGETS-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- G2M_CHECKPOINT-0.480
- MTORC1_SIGNALING-0.450
- MYC_TARGETS_V1-0.450
- OXIDATIVE_PHOSPHORYLATION-0.440
- GLYCOLYSIS-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- ANGIOGENESIS-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01799 | — | cohortA1 | 0.884 |
| 2 | ULC0589T_S77 | — | cohortA1 | 0.884 |
| 3 | SRR2016932 | — | — | 0.882 |
| 4 | TCGA-55-A4DG-01A-11R-A24H-07 | — | cohortA1 | 0.875 |
| 5 | SRR6013520 | — | cohortA1 | 0.870 |
| 6 | AUR-AFSP-TTP1-A-8-0-R-A741-41 | — | D | 0.863 |
| 7 | X3c84ea3b.99a3.4e57.984c.33022811dc60 | — | cohortA1 | 0.860 |
| 8 | SRR11296800 | — | — | 0.852 |
| 9 | SRR8526730 | — | cohortA1 | 0.850 |
| 10 | TCGA-XF-A8HI-01A-11R-A38B-07 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |